Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease

View through CrossRef
SummaryIndividualised antiplatelet therapy and platelet function testing have attracted considerable clinical interest, but several aspects of test performance have not been thoroughly evaluated. We investigated repeatability and concordance of light transmission aggregometry (LTA) induced with arachidonic acid (AA) 1.0 mM, PFA-100® induced with collagen/epinephrine, multiple electrode aggregometry (MEA) induced with AA 0.5 or 0.75 mM and VerifyNow® Aspirin. Patients with stable coronary artery disease (n=43) and healthy individuals (n=21) were included. All tests were performed in duplicate at baseline in healthy individuals and in duplicate for four days in all study participants during aspirin treatment. Serum and urinary thromboxane metabolites were measured several times to evaluate cyclooxygenase-1 inhibition by aspirin. MEA was most sensitive for aspirin as treatment induced a 12-fold difference in AA-induced platelet aggregation. Coefficients of variation for duplicate measurements at baseline (0.4–12%), during aspirin treatment (3–46%) and for day-to-day variability (3–37%) differed markedly between tests and were lowest for VerifyNow®. The prevalence of aspirin low-responsiveness also differed between tests (0–9%) and the agreement was low: kappa≤0.21 for all tests compared with AA-induced LTA (reference test), which correlated best with VerifyNow® (r=0.43, p<0.001). Urinary thromboxane metabolites did not correlate with any platelet function test, whereas serum thromboxane correlated with VerifyNow® Aspirin (r=0.41, p=0.001). Overall, repeatability was moderate and the correlation between tests was low. VerifyNow® Aspirin proved most reproducible, and this was the only assay showing a significant positive correlation with serum thromboxane. This study demonstrated that conclusions based on platelet function testing strongly depend on the assay used.
Title: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
Description:
SummaryIndividualised antiplatelet therapy and platelet function testing have attracted considerable clinical interest, but several aspects of test performance have not been thoroughly evaluated.
We investigated repeatability and concordance of light transmission aggregometry (LTA) induced with arachidonic acid (AA) 1.
0 mM, PFA-100® induced with collagen/epinephrine, multiple electrode aggregometry (MEA) induced with AA 0.
5 or 0.
75 mM and VerifyNow® Aspirin.
Patients with stable coronary artery disease (n=43) and healthy individuals (n=21) were included.
All tests were performed in duplicate at baseline in healthy individuals and in duplicate for four days in all study participants during aspirin treatment.
Serum and urinary thromboxane metabolites were measured several times to evaluate cyclooxygenase-1 inhibition by aspirin.
MEA was most sensitive for aspirin as treatment induced a 12-fold difference in AA-induced platelet aggregation.
Coefficients of variation for duplicate measurements at baseline (0.
4–12%), during aspirin treatment (3–46%) and for day-to-day variability (3–37%) differed markedly between tests and were lowest for VerifyNow®.
The prevalence of aspirin low-responsiveness also differed between tests (0–9%) and the agreement was low: kappa≤0.
21 for all tests compared with AA-induced LTA (reference test), which correlated best with VerifyNow® (r=0.
43, p<0.
001).
Urinary thromboxane metabolites did not correlate with any platelet function test, whereas serum thromboxane correlated with VerifyNow® Aspirin (r=0.
41, p=0.
001).
Overall, repeatability was moderate and the correlation between tests was low.
VerifyNow® Aspirin proved most reproducible, and this was the only assay showing a significant positive correlation with serum thromboxane.
This study demonstrated that conclusions based on platelet function testing strongly depend on the assay used.

Related Results

A study on risk factors of coronary artery disease in Chong Qing city
A study on risk factors of coronary artery disease in Chong Qing city
Objective To investigate the relationship between risk factors and coronary artery disease in Chong Qing city, and to provide scientific basis for preventing and ...
Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity
Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity
Objective: To evaluate and provide management strategies for patients with aspirin or nonselective nonsteroidal antiinflammatory drug (NSAID) sensitivity. Data Sources: Literature ...
Aspirin
Aspirin
Aspirin, considered the prototypic platelet antagonist, has been available for over a century and currently represents a mainstay both in the prevention and treatment of vascular e...
Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year population cohort study in Hong Kong
Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year population cohort study in Hong Kong
Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, has been found to possess protective effects against cancer development in the Western populat...
The effects of transcatheter closure of coronary-pulmonary arterial fistulas in adults
The effects of transcatheter closure of coronary-pulmonary arterial fistulas in adults
Objective Congenital coronary artery fistula (CAF) is an extremely rare congenital anomaly of the coronary artery. We report our experience with Tran catheter occ...
Safety and Efficacy of 14-Day Cold Stored Platelets in Reversing Effects of Aspirin
Safety and Efficacy of 14-Day Cold Stored Platelets in Reversing Effects of Aspirin
Abstract Background: Aspirin is an antiplatelet therapy used to reduce the risk of vascular occlusive events. However, this therapy is associated with an increased r...

Back to Top